DE60235568D1 - Diagnoseverfahren für krebs, das durch den nachweis der deletion des g-csf-exons 3 gekennzeichnet ist - Google Patents

Diagnoseverfahren für krebs, das durch den nachweis der deletion des g-csf-exons 3 gekennzeichnet ist

Info

Publication number
DE60235568D1
DE60235568D1 DE60235568T DE60235568T DE60235568D1 DE 60235568 D1 DE60235568 D1 DE 60235568D1 DE 60235568 T DE60235568 T DE 60235568T DE 60235568 T DE60235568 T DE 60235568T DE 60235568 D1 DE60235568 D1 DE 60235568D1
Authority
DE
Germany
Prior art keywords
deletion
identifying
cancer
csf
diagnosis procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60235568T
Other languages
English (en)
Inventor
Sang-Yup Lee
Ki-Jun Jeong
Hyun-Cheol Chung
Nae-Choon Yoo
Ki-Chang Keum
Won-Min Yoo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medigenes Co Ltd
Original Assignee
Medigenes Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigenes Co Ltd filed Critical Medigenes Co Ltd
Application granted granted Critical
Publication of DE60235568D1 publication Critical patent/DE60235568D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60235568T 2001-09-28 2002-09-28 Diagnoseverfahren für krebs, das durch den nachweis der deletion des g-csf-exons 3 gekennzeichnet ist Expired - Lifetime DE60235568D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20010060826 2001-09-28
PCT/KR2002/001825 WO2003027288A1 (en) 2001-09-28 2002-09-28 Diagnostic method for cancer characterized in the detection of the deletion of g-csf exon 3

Publications (1)

Publication Number Publication Date
DE60235568D1 true DE60235568D1 (de) 2010-04-15

Family

ID=19714831

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60235568T Expired - Lifetime DE60235568D1 (de) 2001-09-28 2002-09-28 Diagnoseverfahren für krebs, das durch den nachweis der deletion des g-csf-exons 3 gekennzeichnet ist

Country Status (9)

Country Link
US (10) US20040247562A1 (de)
EP (1) EP1446485B1 (de)
JP (1) JP4413611B2 (de)
KR (2) KR100523328B1 (de)
CN (1) CN100491527C (de)
AT (1) ATE459646T1 (de)
AU (1) AU2002343900B2 (de)
DE (1) DE60235568D1 (de)
WO (1) WO2003027288A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1828241A1 (de) 2004-12-23 2007-09-05 Laboratoires Serono S.A. G-csf polypeptide und deren verwendungen
KR20070019524A (ko) * 2005-08-12 2007-02-15 메디제네스(주) 암 진단 마커 및 방법
US7909983B2 (en) * 2006-05-04 2011-03-22 Nipro Diagnostics, Inc. System and methods for automatically recognizing a control solution
WO2011109556A2 (en) 2010-03-04 2011-09-09 Pfenex Inc. Method for producing soluble recombinant interferon protein without denaturing
CA2794740C (en) 2010-04-01 2019-12-31 Pfenex Inc. Methods for g-csf production in a pseudomonas host cell

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004548A (en) * 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
EP0791061A4 (de) * 1994-03-04 1998-07-15 Ludwig Inst Cancer Res Tiere mit gezielter genunterbrechung
US6303301B1 (en) * 1997-01-13 2001-10-16 Affymetrix, Inc. Expression monitoring for gene function identification
KR100365482B1 (ko) 1999-12-28 2002-12-26 철 근 김 종양 억제 유전자의 프라이머쌍을 포함하는 암 진단용 벡터

Also Published As

Publication number Publication date
US20050170417A1 (en) 2005-08-04
WO2003027288A1 (en) 2003-04-03
ATE459646T1 (de) 2010-03-15
US20040247562A1 (en) 2004-12-09
JP2005503810A (ja) 2005-02-10
JP4413611B2 (ja) 2010-02-10
KR100523328B1 (ko) 2005-10-24
CN1561395A (zh) 2005-01-05
US20050170416A1 (en) 2005-08-04
WO2003027288A9 (en) 2003-06-05
US20120322684A1 (en) 2012-12-20
EP1446485A1 (de) 2004-08-18
KR100716014B1 (ko) 2007-05-08
AU2002343900B2 (en) 2007-04-26
CN100491527C (zh) 2009-05-27
KR20050098821A (ko) 2005-10-12
US20120329078A1 (en) 2012-12-27
US20140005365A1 (en) 2014-01-02
KR20030027870A (ko) 2003-04-07
EP1446485A4 (de) 2005-05-25
US8324363B2 (en) 2012-12-04
EP1446485B1 (de) 2010-03-03
US20050244856A1 (en) 2005-11-03
US20050158810A1 (en) 2005-07-21
US20050266430A1 (en) 2005-12-01
US20100286381A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
US11326212B2 (en) Biomarkers for non-hodgkin lymphomas and uses thereof
Schmidt et al. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status
Baba et al. A novel allelic variant of serum amyloic A, SAA1γ: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA–amyloidosis
DE69518558D1 (de) Verfahren zur Diagnose von Krebs oder Präkanzerose durch Nachweis IRF-1-spezifischer RNS
JP2006500016A5 (de)
ATE548467T1 (de) Verfahren zur identifizierung von biomarkern mit eignung bei der diagnose biologischer zustände
DK0757723T3 (da) Genetiske ændringer, der korrelerer med lungecarcinoma
EP0960214A1 (de) Diagnose des Krankheitszustandesan HAnd von mRNA-Profilen
WO1997017469A1 (en) Method of predicting the risk of prostate cancer morbidity and mortality
ATE332979T1 (de) Detektion von änderungen von tumor-suppressor genen zur diagnose von krebs
ES2607185T3 (es) GNLY como marcador epigenético para la identificación de linfocitos citolíticos naturales que expresan CD56
DE60235568D1 (de) Diagnoseverfahren für krebs, das durch den nachweis der deletion des g-csf-exons 3 gekennzeichnet ist
KR102112951B1 (ko) 암의 진단을 위한 ngs 방법
WO2003068268A3 (en) Treatment, diagnosis and imaging of disease
RU2440415C1 (ru) Набор синтетических олигонуклеотидов для определения нуклеотидной последовательности кодирующей части гена brca1 и выявления мутаций, ассоциированных с наследственными формами рака молочной железы
KR20170127774A (ko) 유전자의 결실을 이용한 유방암 환자의 예후 예측 방법
ATE483019T1 (de) Aus einem neuroblastom in stufe 4s isoliertenukleinsäuren
ATE440138T1 (de) Mutationen des parkin-gens, zusammensetzungen, verfahren und verwendungen
ES2700790T3 (es) Marcador epigenético para la identificación de linfocitos T il17 positivos en muestras complejas
JP6817608B2 (ja) ヒトにおける骨髄腫瘍の発症又は発症リスクを検査する指標の取得方法、ヒトにおけるｄｄｘ４１遺伝子の体細胞変異の存在又は将来的な発生を予測する指標の取得方法、並びに、これらの検査又は予測のためのキット
Vincent Investigating Stromal Contributions to the Regulation of Cancer Progression
KR20220167709A (ko) 상염색체 우성 중간형 샤르코-마리-투스병 유형 e에 대한 진단용 바이오마커 및 이의 용도
KR20220089835A (ko) 간질환 환자에서 간 섬유화 진행의 예후를 예측하기 위한 분석방법
ATE369426T1 (de) Nukleinsäure- und aminosäuresequenzen von durch hämoglobin induzierbaren genen aus candida albicans und die verwendung dieser sequenzen in reagenzien zur diagnose von disseminierten candida albicans infektionen
CN116555415A (zh) 检测尘肺病易感基因的试剂盒及其应用

Legal Events

Date Code Title Description
8364 No opposition during term of opposition